Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of memantine in pediatric pervasive developmental disorders
2012-001630-33Phase 2Completed
- Sponsor
- Forest Research Institute, Inc
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of memantine in Autism Spectrum Disorder (ASD), sponsored by Forest Research Institute, Inc. Primary endpoint: Long-term safety and tolerability of memantine. Started Jun 2012; status: completed.
02
Drugs
memantine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2012-001630-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001630-33.